ORYZON to give updates on corporate progress in February and March
Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in February and March.
Oryzon will participate at the BIO CEO & Investor Conference 2022, to be held in New York and virtually on February 14-17. Dr. Carlos Buesa, Oryzon’s CEO, and Dr. Saikat Nandi, Oryzon’s Global Chief Business Officer, will hold one-to-one meetings with pharmaceutical companies and global investors. During this event Dr. Buesa will present a corporate update on February 14 at 11:00 am ET. Click on link for more info about the BIO CEO & Investor conference
Oryzon has been invited to participate at the Epigenetics Symposium: From Genes to Chromatin to Therapeutics, hosted by the Cancer Epigenetics Institute and the Fox Chase Cancer Center, to be held in Philadelphia and virtually on March 2. Dr. Ana Limón, Oryzon’s Senior VP of Clinical Development and Global Medical Affairs will give a short talk as part of a session with leading industry members discussing epigenetic-related therapies. Click on link for more info about this Epigenetics Symposium
Oryzon will also attend the BioMed Event 2022, which will be held on March 8 in Paris, France, where Dr. Buesa will present a corporate update. Click on link for more info about the BioMed Event
Executive directors of the company will also attend the Barclays Global Healthcare Conference, to be held in Miami on March 15-17. Dr. Buesa will present a corporate update on March 16 at 16:20 ET.
More info about the company and contact in the file attached.